A systematic pan-cancer analysis identifies RIOK3 as an immunological and prognostic biomarker. 2022

Jian Li, and Ruili Sun, and Lixiang He, and Guoyi Sui, and Wenyu Di, and Jian Yu, and Wei Su, and Zenggang Pan, and Yu Zhang, and Jinghang Zhang, and Feng Ren
Department of Pathology, The First Affiliated Hospital of Xinxiang Medical University Xinxiang 453003, Henan, China.

OBJECTIVE Despite recent research highlighting the critical function of RIO kinase 3 (RIOK3) in a variety of malignancies, a comprehensive evaluation of RIOK3 in human tumors is absent. Our study helps to clarify the molecular mechanism of RIOK3 in carcinogenesis from multiple perspectives. METHODS Our research looked into the potential oncogenic role of RIOK3 in 33 cancers using TCGA (The Cancer Genome Atlas), GTEx (Genotype-Tissue Expression Project), GEO (Gene Expression Omnibus) datasets, and several bioinformatics tools. RESULTS RIOK3 expression in tumors is disordered compared to normal tissue, and it is highly linked with the level of MMR (Mismatch repair) gene mutations and DNA methyltransferase expression. According to univariate survival analysis, it could be used as an independent prognostic factor. Further investigation demonstrated that RIOK3 expression was correlated with cancer-associated fibroblast, neutrophil, and endothelial infiltration levels in kidney cancer and was positively correlated with the expression of immune checkpoint markers in different cancers. The functional pathways of RIOK3 also included cell-cell adhesion, protein phosphorylation, and innate immune-related functions. CONCLUSIONS These findings suggest that RIOK3 could be used as an immunological and prognostic biomarker in various malignant tumors.

UI MeSH Term Description Entries

Related Publications

Jian Li, and Ruili Sun, and Lixiang He, and Guoyi Sui, and Wenyu Di, and Jian Yu, and Wei Su, and Zenggang Pan, and Yu Zhang, and Jinghang Zhang, and Feng Ren
January 2022, Journal of oncology,
Jian Li, and Ruili Sun, and Lixiang He, and Guoyi Sui, and Wenyu Di, and Jian Yu, and Wei Su, and Zenggang Pan, and Yu Zhang, and Jinghang Zhang, and Feng Ren
September 2022, Journal of cellular and molecular medicine,
Jian Li, and Ruili Sun, and Lixiang He, and Guoyi Sui, and Wenyu Di, and Jian Yu, and Wei Su, and Zenggang Pan, and Yu Zhang, and Jinghang Zhang, and Feng Ren
January 2021, Frontiers in immunology,
Jian Li, and Ruili Sun, and Lixiang He, and Guoyi Sui, and Wenyu Di, and Jian Yu, and Wei Su, and Zenggang Pan, and Yu Zhang, and Jinghang Zhang, and Feng Ren
April 2023, Scientific reports,
Jian Li, and Ruili Sun, and Lixiang He, and Guoyi Sui, and Wenyu Di, and Jian Yu, and Wei Su, and Zenggang Pan, and Yu Zhang, and Jinghang Zhang, and Feng Ren
July 2022, FASEB journal : official publication of the Federation of American Societies for Experimental Biology,
Jian Li, and Ruili Sun, and Lixiang He, and Guoyi Sui, and Wenyu Di, and Jian Yu, and Wei Su, and Zenggang Pan, and Yu Zhang, and Jinghang Zhang, and Feng Ren
January 2023, Oncology research,
Jian Li, and Ruili Sun, and Lixiang He, and Guoyi Sui, and Wenyu Di, and Jian Yu, and Wei Su, and Zenggang Pan, and Yu Zhang, and Jinghang Zhang, and Feng Ren
May 2023, Aging,
Jian Li, and Ruili Sun, and Lixiang He, and Guoyi Sui, and Wenyu Di, and Jian Yu, and Wei Su, and Zenggang Pan, and Yu Zhang, and Jinghang Zhang, and Feng Ren
September 2023, Aging,
Jian Li, and Ruili Sun, and Lixiang He, and Guoyi Sui, and Wenyu Di, and Jian Yu, and Wei Su, and Zenggang Pan, and Yu Zhang, and Jinghang Zhang, and Feng Ren
October 2023, European journal of medical research,
Jian Li, and Ruili Sun, and Lixiang He, and Guoyi Sui, and Wenyu Di, and Jian Yu, and Wei Su, and Zenggang Pan, and Yu Zhang, and Jinghang Zhang, and Feng Ren
January 2022, BMC genomic data,
Copied contents to your clipboard!